Ìhsan Karadoǧan

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Plasma Protein Z Levels Inversely Correlate with Plasma Interleukin-6 Levels in Patients with Acute Leukemia and Non-Hodgkin’s Lymphoma

Levent Ündar, Ìhsan Karadoǧan, Firuzan Öztürk · Thrombosis Research · 1999 · 35 citations

Veterinary Medicine, Hematology, Immunology +8

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Ayşe Salihoğlu, Tuğrul Elverdi, Ìhsan Karadoǧan et al. · Annals of Hematology · 2014 · 33 citations · Full text

Medicine, Oncology, Pharmacotherapy +14